#h7n9 — Public Fediverse posts

Elicitation of Potent #H5N1 - and #H7N9-Neutralizing #Antibody Responses in Rh. Macaques by Sequential Heterologous #Vaccination with #mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins, https://etidiohnew.blogspot.com/2026/09/elicitation-of-potent-h5n1-and-h7n9.html

Elicitation of Potent #H5N1 - and #H7N9-Neutralizing #Antibody Responses in Rh. Macaques by Sequential Heterologous #Vaccination with #mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins, https://etidiohnew.blogspot.com/2026/09/elicitation-of-potent-h5n1-and-h7n9.html

Elicitation of Potent #H5N1 - and #H7N9-Neutralizing #Antibody Responses in Rh. Macaques by Sequential Heterologous #Vaccination with #mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins, https://etidiohnew.blogspot.com/2026/09/elicitation-of-potent-h5n1-and-h7n9.html

Elicitation of Potent #H5N1 - and #H7N9-Neutralizing #Antibody Responses in Rh. Macaques by Sequential Heterologous #Vaccination with #mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins, https://etidiohnew.blogspot.com/2026/09/elicitation-of-potent-h5n1-and-h7n9.html

Elicitation of Potent #H5N1 - and #H7N9-Neutralizing #Antibody Responses in Rh. Macaques by Sequential Heterologous #Vaccination with #mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins, https://etidiohnew.blogspot.com/2026/09/elicitation-of-potent-h5n1-and-h7n9.html

#Safety and #immunogenicity of ascending doses of #influenza A(#H7N9) inactivated #vaccine with or without MF59®, https://etidiohnew.blogspot.com/2025/01/safety-and-immunogenicity-of-ascending.html

A synthetic #TLR4 agonist significantly increases #humoral immune #responses and the protective ability of an #MDCK-cell-derived inactivated #H7N9 #vaccine in #mice, Arch Virol.: https://link.springer.com/article/10.1007/s00705-024-06082-8

Antigenically divergent H7N9 viruses pose a potential threat to public #health, with the poor #immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines.

A Phase 2 Clinical Trial to Evaluate the #Safety, Reactogenicity, and #Immunogenicity of Different Prime-Boost #Vaccination Schedules of '13 & '17 #H7N9 Inactivated #Influenza Virus Vaccines Administered with & without #AS03 Adjuvant in Healthy US Adults, Clin Infect Dis.: https://doi.org/10.1093/cid/ciae173

Administering adjuvant with 2nd H7N9 IIV dose & extending boost interval to 4 mos resulted in higher peak Ab responses. These observations can inform strategic approaches for pandemic preparedness.

#Immunogenicity and safety of varying dosages of a fifth-wave #influenza A/ #H7N9 inactivated #vaccine given with and without #AS03 adjuvant in healthy adults https://pubmed.ncbi.nlm.nih.gov/38105137/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1LGAx__djGAJ9poBzWGqPtjEbBDtz4ipSRRPUplmgHEyyF_Ihj&fc=None&ff=20231218031744&v=2.18.0